EBM Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Drisko, J. E.
Right arrow Articles by Hickey, G. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Drisko, J. E.
Right arrow Articles by Hickey, G. J.
Proceedings of the Society for Experimental Biology and Medicine 222:70-77 (1999)
© 1999 Society for Experimental Biology and Medicine


Original Article

Administration of a Nonpeptidyl Growth Hormone Secretagogue, L-163,255, Changes Somatostatin Pattern, But Has No Effect on Patterns of Growth Hormone-Releasing Factor in the Hypophyseal-Portal Circulation of the Conscious Pig

J. E. Drisko*,1, T. D. Faidley{dagger}, D. Zhang{ddagger}, T. J. McDonald#, S. Nicolich{dagger}, D. F. Hora§, P. Cunningham§, C. Li#, E. Rickes*, L. McNamara*, C. Chang*, R. G. Smith and G. J. Hickey*


* Departments of Basic Animal Science Research,
{dagger} Branchburg Farm,
{ddagger} Biometrics Research,
§ Laboratory Animal Resources, Merck Research Laboratories, Rahway, New Jersey 07065;
# Laboratory for Pregnancy and Newborn Research, New York State College of Veterinary Medicine, Cornell University, Ithaca, New York 14853; and
Department of Cell Biology, Baylor College of Medicine, and Huffington Center on Aging, Houston, Texas 77030

The activity of the growth hormone secretagog, L-163,255, on growth hormone (GH), growth hormone-releasing factor (GRF), and somatostatin (SRIF) levels was evaluated in a porcine model of hypophyseal portal blood (HPB) collection. Young, castrated pigs had HPB and jugular blood collected for {approx} 300 min. The blood collection was divided into discrete periods: baseline (BL) {approx} 180 min; GH response period (RSP) {approx} 90 min; and positive control period following a GRF bolus, 30 min. RSP was divided into a dominant response period (DOM) and a tail (TL). The spontaneous relationship between HPB GRF and SRIF and peripheral GH during BL has been reported (Proc Soc Exp Biol Med 217:188–196, 1998). The apex of the GH pulse resulting from L-163,255 administration was nonrandomly associated (P < 0.05) with descending periods of SRIF troughs. Frequency and amplitude of GRF and SRIF pulses, and frequency and depth of SRIF troughs were not different between BL and the beginning of DOM (the 20–30 min of GH increase). GH AUC was significantly greater (P < 0.05) for DOM compared to BL and TL, and for TL compared to BL. GRF AUC tended to be greater (P < 0.1) for RSP compared to BL, but the majority of the increase was in the TL period. There were no significant differences in the SRIF AUCs between the sampling periods. Furthermore, in a separate experiment, fos activity (a marker of neuronal activation) in the hypothalamus of pigs was examined after either L-163,255 (1x or 4x), isotonic saline (control), or hypertonic saline (positive control) administration. There were no differences in fos activity in the GRF, SRIF, or CRH immunopositive neurons between L-163,255 treatment and control. The pituitaries of the L-163,255-treated pigs showed marked fos activation compared to the controls. In conclusion, L-163,255 in pigs has its primary effect at the level of the anterior pituitary.




This article has been cited by other articles:


Home page
Endocr. Rev.Home page
R. G. Smith
Development of Growth Hormone Secretagogues
Endocr. Rev., May 1, 2005; 26(3): 346 - 360.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
A. J. van der Lely, M. Tschop, M. L. Heiman, and E. Ghigo
Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin
Endocr. Rev., June 1, 2004; 25(3): 426 - 457.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the Society for Experimental Biology and Medicine.